BLA 761179 · Jazz Pharms
Rylaze
Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn · Intramuscular · Asparagine-specific Enzyme
NovelOrphanCDER novel approval, Jun 30, 2021: To treat acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who are allergic to E. coli-derived asparaginase products, as a component of a chemotherapy regimen
Last checked: Nov 20, 2026Latest source record: Apr 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jun 30, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
37
12 Phase 3, 6 recruiting
FAERS reports
344
165 serious, 19 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 1, 2025.
RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. RYLAZE is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. ( 1 )
Mechanism: Asparaginase erwinia chrysanthemi (recombinant)-rywn is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The pharmacological effect of RYLAZE is based on the killing of leukemic cells due to depletion of plasma asparagine. Leukemic cells with low expression of asparagine synthetase have a reduced ability to synthesize asparagine, and therefore depend on an exogenous source of asparagine for survival.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 18, 2022 Supplement 1 · Efficacy OrphanLetterLabel
- Jun 30, 2021 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
- RYLAZE · ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN 10MG/0.5ML · INJECTABLE, INTRAMUSCULAR · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Asparaginase Erwinia Chrysanthemi (Recombinant)" as an intervention, any sponsor and status, largest first.
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00002744 · 1,970 participants · Start May 1996 · Primary completion Mar 2007
Drug: asparaginase; cyclophosphamide and 11 more · For: Leukemia
Sites: Long Beach, California; Los Angeles, California; Orange, California · 34 sites in all
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT04293562 · 1,400 participants (planned) · Start Jul 21, 2020 · Primary completion Jun 30, 2029
Drug: Asparaginase Erwinia chrysanthemi; Cytarabine and 9 more · For: Acute Myeloid Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 206 sites in all
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaPivotal-lookingActive, not recruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT03117751 · 790 participants · Start Mar 29, 2017 · Primary completion Sep 30, 2026
Drug: Prednisone; Vincristine and 21 more · For: Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
Sites: Palo Alto, California; San Diego, California; Peoria, Illinois · 8 sites in all
- Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
St. Jude Children's Research HospitalAcademic, hospital or other
NCT00549848 · 600 participants · Start Oct 29, 2007 · Primary completion Sep 26, 2020
Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine; Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib · For: Acute Lymphoblastic Leukemia
Sites: Memphis, Tennessee
- Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and AdolescentsPivotal-lookingActive, not recruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT03020030 · 560 participants · Start Mar 3, 2017 · Primary completion Nov 30, 2026
Drug: Pegaspargase; Erwinia asparaginase and 13 more · For: Acute Lymphoblastic Leukemia, Pediatric
Sites: Boston, Massachusetts; New Brunswick, New Jersey; Buffalo, New York · 9 sites in all
- Therapy for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
St. Jude Children's Research HospitalAcademic, hospital or other
NCT00137111 · 501 participants · Start Jul 8, 2000 · Primary completion Nov 2010
Drug: Prednisone, Dexamethasone, Vincristine, Daunorubicin; Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase and 2 more · For: Lymphoblastic Leukemia, Acute
Sites: Memphis, Tennessee; Fort Worth, Texas
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Pivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT04546399 · 461 participants (planned) · Start Dec 17, 2020 · Primary completion Jun 30, 2028
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 9 more · For: Down Syndrome; Recurrent B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 229 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use33
- hyperammonaemia31
- febrile neutropenia28
- nausea26
- hypersensitivity21
- pancreatitis20
- urticaria19
- rash18
- vomiting17
- neutropenia15
- anaphylactic reaction14
- ammonia increased12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 44 |
| 2023 | 69 |
| 2024 | 104 |
| 2025 | 84 |
| 2026 | 43 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Rylaze (Asparaginase Erwinia-Rywn) · HCPCS J9021
2024 spending
$877K
Beneficiaries
n/a
25 claims
Per beneficiary
n/a
2024 ASP limit $51.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $468,527 |
| 2023 | $474,942 |
| 2024 | $876,744 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Jazz Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.